Hendrik Seeliger

2.6k total citations
64 papers, 1.8k citations indexed

About

Hendrik Seeliger is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Hendrik Seeliger has authored 64 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 23 papers in Molecular Biology and 17 papers in Surgery. Recurrent topics in Hendrik Seeliger's work include Pancreatic and Hepatic Oncology Research (15 papers), Cancer Cells and Metastasis (7 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Hendrik Seeliger is often cited by papers focused on Pancreatic and Hepatic Oncology Research (15 papers), Cancer Cells and Metastasis (7 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Hendrik Seeliger collaborates with scholars based in Germany, United States and Slovakia. Hendrik Seeliger's co-authors include Christiane J. Bruns, Karl‐Walter Jauch, Axel Kleespies, Ivan Ischenko, Markus Guba, Martin E. Kreis, Martin Eichhorn, Markus Albertsmeier, Markus Rentsch and Peter Čamaj and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Hendrik Seeliger

58 papers receiving 1.8k citations

Peers

Hendrik Seeliger
Hendrik Seeliger
Citations per year, relative to Hendrik Seeliger Hendrik Seeliger (= 1×) peers Amal Melhem‐Bertrandt

Countries citing papers authored by Hendrik Seeliger

Since Specialization
Citations

This map shows the geographic impact of Hendrik Seeliger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hendrik Seeliger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hendrik Seeliger more than expected).

Fields of papers citing papers by Hendrik Seeliger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hendrik Seeliger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hendrik Seeliger. The network helps show where Hendrik Seeliger may publish in the future.

Co-authorship network of co-authors of Hendrik Seeliger

This figure shows the co-authorship network connecting the top 25 collaborators of Hendrik Seeliger. A scholar is included among the top collaborators of Hendrik Seeliger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hendrik Seeliger. Hendrik Seeliger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hering, Nina A., Marco Arndt, Johannes C. Lauscher, et al.. (2023). Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer. Cancers. 15(2). 456–456. 12 indexed citations
2.
Hering, Nina A., Carsten Kamphues, Johannes C. Lauscher, et al.. (2023). Near-infrared Fluorescence Imaging for Detecting Pancreatic Liver Metastasis in an Orthotopic Athymic Mouse Model. In Vivo. 37(2). 519–523.
3.
Sasaki, Kazunari, Jane Wang, Nikolaos Andreatos, et al.. (2022). Is Laterality Prognostic in Resected KRAS-Mutated Colorectal Liver Metastases? A Systematic Review and Meta-Analysis. Cancers. 14(3). 799–799. 6 indexed citations
4.
Hering, Nina A., Marco Arndt, Sefer Elezkurtaj, et al.. (2022). Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Journal of Cancer Research and Clinical Oncology. 149(1). 271–280. 7 indexed citations
5.
Nachbichler, Silke Birgit, Dirk Böhmer, Carsten Kamphues, et al.. (2022). Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. Radiation and Environmental Biophysics. 61(2). 255–262. 2 indexed citations
6.
Hering, Nina A., Benjamin Weixler, Raoul A. Droeser, et al.. (2021). Blockage of Cholinergic Signaling via Muscarinic Acetylcholine Receptor 3 Inhibits Tumor Growth in Human Colorectal Adenocarcinoma. Cancers. 13(13). 3220–3220. 21 indexed citations
7.
Hering, Nina A., Lisa Hartmann, Peter Čamaj, et al.. (2020). Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Cellular Oncology. 44(1). 167–177. 18 indexed citations
8.
Beyer, Katharina, Carsten Kamphues, Hendrik Seeliger, et al.. (2019). Laparoscopic versus open gastrectomy for locally advanced gastric cancer: a systematic review and meta-analysis of randomized controlled studies. World Journal of Surgical Oncology. 17(1). 68–68. 49 indexed citations
9.
Seeliger, Hendrik, Gerald Assmann, Yue Zhao, et al.. (2018). Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. BMC Cancer. 18(1). 1049–1049. 19 indexed citations
10.
Knösel, Thomas, Yue Zhao, Gerald Assmann, et al.. (2018). Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 144(10). 1887–1897. 13 indexed citations
11.
Zhao, Yue, A. Altendorf-Hofmann, Peter Čamaj, et al.. (2017). Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 143(6). 1061–1068. 27 indexed citations
12.
Gallmeier, Eike, Lydia Kriegl, Sabina Berezowska, et al.. (2013). Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery. PLoS ONE. 8(2). e56760–e56760. 20 indexed citations
13.
Schäfer, Claus, Hendrik Seeliger, Gerald Assmann, et al.. (2011). Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine. 16(8). 1776–1791. 38 indexed citations
14.
Čamaj, Peter, Hendrik Seeliger, Ivan Ischenko, et al.. (2009). EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biological Chemistry. 390(12). 1293–1302. 68 indexed citations
15.
Kleespies, Axel, Hendrik Seeliger, Martin Eichhorn, et al.. (2009). Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. International Journal of Colorectal Disease. 24(9). 1097–1109. 81 indexed citations
16.
Fröhlich, Eckhart, et al.. (2008). Stellenwert der Feinnadelpunktion bei Nebennierentumoren. Ultraschall in der Medizin - European Journal of Ultrasound. 16(2). 90–93. 1 indexed citations
17.
Ischenko, Ivan, Hendrik Seeliger, Moshe Schaffer, Karl‐Walter Jauch, & Christiane J. Bruns. (2008). Cancer Stem Cells: How can we Target them?. Current Medicinal Chemistry. 15(30). 3171–3184. 71 indexed citations
18.
Ischenko, Ivan, Peter Čamaj, Hendrik Seeliger, et al.. (2008). Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene. 27(57). 7212–7222. 60 indexed citations
19.
Seeliger, Hendrik, Hanno Spatz, & Karl‐Walter Jauch. (2003). Minimal Residual Disease in Gastric Cancer. Recent results in cancer research. 162. 79–87. 14 indexed citations
20.
Hackelsberger, Andreas, P. Frühmorgen, H. Weiler, et al.. (1995). Endoscopic Polypectomy and Management of Colorectal Adenomas with Invasive Carcinoma. Endoscopy. 27(2). 153–158. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026